New hope for Hard-to-Treat cancers: targeted combo trial opens

NCT ID NCT06922591

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 30 times

Summary

This study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The goal is to find safe doses and see if the combinations shrink tumors. About 183 adults with advanced or metastatic disease who have already tried standard therapy will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact

  • Georgetown University Medical Center

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

    Contact

  • Huntsman Cancer Institute, University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

  • Mayo Clinic Cancer Center

    RECRUITING

    Rochester, Minnesota, 55905-0001, United States

    Contact

  • Mayo Clinic Jacksonville

    RECRUITING

    Jacksonville, Florida, 32224, United States

    Contact

  • Mayo Clinic Scottsdale

    RECRUITING

    Scottsdale, Arizona, 85259-5452, United States

    Contact

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 11065, United States

    Contact

  • NEXT Dallas

    RECRUITING

    Irving, Texas, 74039, United States

    Contact

  • NEXT Oncology

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact

  • Nebraska Cancer Specialists

    RECRUITING

    Omaha, Nebraska, 68124, United States

    Contact

  • Northwestern Memorial Hospital

    RECRUITING

    Chicago, Illinois, 60611-2908, United States

    Contact

  • Sarah Cannon Research Institute Denver

    RECRUITING

    Denver, Colorado, 80218, United States

    Contact

  • University of Indiana

    RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact

  • University of Iowa Health Care

    RECRUITING

    Iowa City, Iowa, 52242, United States

    Contact

  • University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599-7305, United States

    Contact

  • University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

Conditions

Explore the condition pages connected to this study.